Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365093 | 0.89 | SSTR4 (0.49) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL4365086 | 0.89 | SSTR4 (0.49) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL22199265 | 0.89 | BTK (0.41) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL4369925 | 0.89 | SSTR4 (0.49) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL1457503 | 0.89 | BTK (0.41) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL4365082 | 0.89 | SSTR4 (0.49) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL4369929 | 0.89 | SSTR4 (0.49) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL1468726 | 0.89 | BTK (0.41) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL1531695 | 0.89 | BTK (0.41) | BTKGAANFKB1NFKB2RELA | |
| SCHEMBL1468729 | 0.89 | BTK (0.41) | BTKGAANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | BTK 1068/4885GAA 173/4885NFKB1 930/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | BTK 1068/4885GAA 173/4885NFKB1 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.